---
search:
  boost: 2 
---

# Attention Deficit Hyperactivity Disorder Agents

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                                                             | Generic Name | Quantity | Time (Days) |
| :-------------------------------------------------------------------- | :----------- | :------: | :---------: |
| Amphetamine/Dextroamphetamine ER <sup>AR QL</sup>        |  Amphetamine-Dextroamphetamine ER Cap (all strengths)            |   34       |   34          |
| Amphetamine/Dextroamphetamine IR <sup>AR QL</sup>                                      |     Amphetamine-Dextroamphetamine Tab (all strengths excl 30 MG)        |     102    |  34           |
| Amphetamine/Dextroamphetamine IR <sup>AR QL</sup>                                      |     Amphetamine-Dextroamphetamine Tab 30 MG         |   68       |    34         |
| Atomoxetine Cap <sup>AR QL</sup>                                                     |  Atomoxetine HCI Cap (all strengths excl 80 MG & 100 MG)            |   68       |   34          |
| Atomoxetine Cap <sup>AR QL</sup>                                                     |  Atomoxetine HCI Cap 80 MG & 100 MG            |  34        |     34        |
| Clonidine ER                                                           |              |          |             |
| Concerta <sup>AR QL</sup>                          | Methylphenidate HCI ER Tab Osmotic (all strengths excl 36 MG)           |     34     | 34            |
| Concerta <sup>AR QL</sup>                          | Methylphenidate HCI ER Tab Osmotic 36 MG         |     68     |  34           |
| Dexmethylphenidate Tab <sup>AR QL</sup>                                                | Dexmethylphenidate HCI Tab (all strengths)             |  68        |     34        |
| Dexmethylphenidate Tab <sup>AR QL</sup>                                                | Dexmethylphenidate HCI ER Cap (all strengths)      | 34         |  34           |
| Dexmethylphenidate ER (generic of Focalin XR) <sup>AR QL</sup>                        |              |          |             |
| Dextroamphetamine ER Cap <sup>AR QL</sup>                                       |   Dextroamphetamine Sulfate ER Cap (all strengths excl 15 MG)           |      34    |   34          |
| Dextroamphetamine ER Cap <sup>AR QL</sup>                                       |   Dextroamphetamine Sulfate ER Cap 15 MG          |      136    |   34          |
| Dextroamphetamine IR Tab <sup>AR QL</sup>                                                | Dextroamphetamine Sulfate Tab (all strengths)             |      102    |     34      |
| Dextroamphetamine Sol <sup>AR</sup>                                             |              |          |             |
| Dyanavel XR <sup>AR</sup>                              |              |          |             |
| Guanfacine ER <sup>QL</sup>                                                          | Guanfacine HCI ER Tab (all strengths)             |    34      |   34          |
| Methylphenidate ER Cap <sup>AR QL</sup> (generic of Metadate CD, Ritalin LA)           |  Methylphenidate HCI CR Cap (all strengths)            |  34        | 34            |
| Methylphenidate ER Tab <sup>AR QL</sup> (generic of Concerta, Methylin ER, Ritalin SR) |  Methylphenidate HCI CR Tab (all strengths excl 10 MG & 20 MG)           |      34    |      34       |
| Methylphenidate ER Tab <sup>AR QL</sup> (generic of Concerta, Methylin ER, Ritalin SR) |  Methylphenidate HCI CR Tab 10 MG & 20 MG         |     102     |    34         |
| Methylphenidate Sol <sup>AR QL</sup>                                                 |   Methylphenidate HCI Soln 5 MG / 5 ML           |  2040        |       34      |
| Methylphenidate Sol <sup>AR QL</sup>                                                 |   Methylphenidate HCI Soln 10 MG / 5 ML           |      1020    |  34           |
| Methylphenidate Tab <sup>AR QL</sup>                                                    | Methylphenidate HCI Tab (all strengths)             |      102    |       34      |
| Procentra <sup>AR</sup>                        |              | | |
| Qelbree <sup>ST</sup>                                                             |              |          |             |
| Quillichew ER <sup>AR</sup>                                                        |              |          |             |
| Quillivant XR <sup>AR</sup>                                                          |              |          |             |
| Ritalin LA <sup>AR QL</sup>                           | Methylphenidate HCI Tab (all strengths)           | Determined pursuant to PA         |    Determined pursuant to PA         |
| Vyvanse Cap <sup>QL</sup>                                                           |  Lisdexamfetamine Dimesylate Cap (all strengths)       |  34        |   34          |

### Non-Preferred

| Non-Preferred                                         | Generic Name | Quantity | Time (Days) |
| :---------------------------------------------------- | :----------- | :------: | :---------: |
| Adhansia XR <sup>AR</sup>                                           |              |          |             |
| Adzenys ER                                            |              |          |             |
| Adzenys XR ODT                                        |              |          |             |
| Amphetamine Tab                                       |              |          |             |
| Azstarys <sup>AR</sup>                                             |              |          |             |
| Cotempla XR ODT <sup>AR</sup>                                      |              |          |             |
| Daytrana <sup>AR BvG</sup>                                          |              |          |             |
| Evekeo ODT                                            |              |          |             |
| Jornay PM <sup>AR</sup>                                            |              |          |             |
| Methamphetamine                                       |              |          |             |
| Methylphenidate Chewable Tab <sup>AR QL</sup>                          | Methylphenidate HCI Chew Tab (all strengths)             |  Determined pursuant to PA        |    Determined pursuant to PA         |
| Methylphenidate ER <sup>AR QL</sup>(generic of Aptensio XR, Relexxii) |              |          |             |
| Mydayis <sup>AR QL</sup>                                              | Amphetamine / Dextroapmphetamine 3-Bead ER Cap (all strengths)             |  Determined pursuant to PA        | Determined pursuant to PA        |
| Vyvanse Chewable Tab                                  |              |          |             |
| Zenzedi <sup>AR QL</sup>                                               | Dextroamphetamine Sulfate Tab (all strengths)            |    Determined pursuant to PA      | Determined pursuant to PA            |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

### Step Therapy

Step Therapy Criteria

- Must have had an inadequate clinical response of at least **30 days** with atomoxetine **OR** at least **two preferred** stimulants

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **three preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Information

- Requests for non-preferred immediate-release formulations must have all required trials with preferred immediate-release drugs, and requests for non-preferred extended-release formulations must have all required trials with preferred extended-release drugs
- For patients established on drugs that change from preferred to non-preferred on January 1, a prior authorization is **NOT** required until **after** June 30th of that year.

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

AR - Dextroamphetamine Solution: a PA is required for patients over 12 years old

AR - Methylphenidate Solution: a PA is required for patients over 12 years old

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=34)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=15)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
